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Abstract
The discovery of genes and molecular pathways involved in the formation of brain metastasis would direct the development 
of therapeutic strategies to prevent this deadly complication of cancer. By comparing gene expression profiles of Estrogen 
Receptor negative (ER-) primary breast tumors between patients who developed metastasis to brain and to organs other than 
brain, we found that T lymphocytes promote the formation of brain metastases. To functionally test the ability of T cells to 
promote brain metastasis, we used an in vitro blood–brain barrier (BBB) model. By co-culturing T lymphocytes with breast 
cancer cells, we confirmed that T cells increase the ability of breast cancer cells to cross the BBB. Proteomics analysis of 
the tumor cells revealed Guanylate-Binding Protein 1 (GBP1) as a key T lymphocyte-induced protein that enables breast 
cancer cells to cross the BBB. The GBP1 gene appeared to be up-regulated in breast cancer of patients who developed 
brain metastasis. Silencing of GBP1 reduced the ability of breast cancer cells to cross the in vitro BBB model. In addition, 
the findings were confirmed in vivo in an immunocompetent syngeneic mouse model. Co-culturing of ErbB2 tumor cells 
with activated T cells induced a significant increase in Gbp1 expression by the cancer cells. Intracardial inoculation of the 
co-cultured tumor cells resulted in preferential seeding to brain. Moreover, intracerebral outgrowth of the tumor cells was 
demonstrated. The findings point to a role of T cells in the formation of brain metastases in ER- breast cancers, and provide 
potential targets for intervention to prevent the development of cerebral metastases.
Keywords Brain metastasis · Blood–brain barrier · T cell response · GBP1
Introduction
Breast cancer is among the tumors that most frequently 
metastasize to brain [30, 37, 38, 40, 43, 49, 57]. The appear-
ance of metastases in brain invariably defines the terminal 
stage of disease for women suffering from disseminated 
breast cancer and the prevention of cerebral spread would 
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significantly improve their survival [44]. The formation of 
cerebral metastases depends on the capability of circulating 
tumor cells to successfully penetrate the blood–brain barrier 
(BBB). Various genes and pathways have been associated 
with seeding of breast cancer cells to various organs and 
the rise of brain metastases in particular [6, 32, 47, 52, 54]. 
Several associations between innate features of the primary 
tumors and their propensity to intracerebral seeding have 
been reported. HER2-enriched (HER2 +) and triple-negative 
(TNBC) primary tumors are at higher risk for developing 
brain metastases relative to the hormone receptor-positive 
tumors [17, 18, 29, 53, 59]. So far, ST6GALNAC5 is the only 
specific gene that was found to mediate the formation of 
brain metastases of a human breast cancer-derived cell line 
when injected in mice. Moreover, its expression in human 
breast cancer samples appeared to be associated with the 
occurrence of cerebral metastases [3]. However, the iden-
tification of pathways associated with brain metastasis is 
necessary to elucidate the mechanisms of crossing the BBB 
and developing strategies to prevent the formation of brain 
metastasis.
Here, we sought pathways specifically involved in the for-
mation of cerebral metastases of breast cancer by compar-
ing RNA expression profiles of primary ER- breast cancer 
samples of patients who developed cerebral metastases, with 
those who developed metastasis to other organs but not to 
brain. We discovered that the T cell response is crucial for 
the development of brain metastases. In both in vitro stud-
ies using a BBB model and in vivo studies using a mouse 
model, T cells appear to change the expressional profiles of 
the breast cancer cells and facilitate their passage through 
the BBB. Guanylate-binding protein 1 (GBP1) is prominent 
among the involved proteins and its expression appears to 
be upregulated in the primary tumor specimens. Silencing 
of GBP1 significantly decreased the ability of breast cancer 
cells to cross the BBB. The involvement and specific action 
of T lymphocytes in the process of cerebral metastasis is 
novel, and opens new therapeutic opportunities for prevent-
ing tumor cells to enter the brain.
Methods
Tissue sample selection
To identify genes and pathways involved in the formation of 
brain metastasis, we exclusively used specimens of primary 
tumors, and did not use specimens of metastatic sites. Fresh 
frozen (FF) tissue specimens of 22 primary breast cancer 
patients who developed metastasis to brain and/or to other 
organs were selected. Two groups of samples were com-
pared; those from patients who had developed brain metas-
tasis (exclusively or in addition to a maximum of 2 organs; 
n = 13) and those from women who developed metastases to 
a maximum of three organs (n = 9). None of the 22 patients 
had received adjuvant therapy (chemo- or hormonal therapy) 
prior to developing metastases, all samples were ER- and 
none of the patients had more than three metastatic sites. The 
relevant clinical data are provided in Table 1. In addition, 
we used 20 primary breast cancer samples for independ-
ent validations from patients of whom 13 developed brain 
metastasis. This study was approved by the Medical Ethics 
Committee of the Erasmus Medical Center, Rotterdam, The 
Netherlands (MEC 02·953) and performed in adherence to 
the Code of Conduct of the Federation of Medical Scientific 
Societies in The Netherlands (http ://www.fmwv .nl/).
Morphological assessment
5 µm H&E sections from each sample were prepared before 
and after sectioning for RNA isolation. To ascertain the ori-
gin of the tumor, the percentages of the invasive tumor cells, 
inflammatory infiltrates and the presence of necrosis were 
taken into consideration (JMK).
RNA extraction and purification and quality control
Total RNA from FF tissue samples was extracted from 20 to 
30 sections of 30 μm (depending on the size of the sample) 
using RNABee reagent according the supplier’s instructions 
(Campro Scientific, Veenendaal, The Netherlands) [50]. 
Following isolation, RNA was stored in RNase/DNase-free 
water at − 80 °C. The quantity and quality of the isolated 
RNA was assessed by nanodrop. Samples were excluded if 
the yield did not reach the minimum requirement of 1000 ng.
Gene expression profiling
Illumina Whole-Genome cDNA-mediated Annealing, Selec-
tion, extension and Ligation (WG-DASL) assay was used 
to profile the samples. In the assay, 24,526 annotated tran-
scripts corresponding to 18,391 unique genes are measured. 
The WG-DASL assay was performed according to the manu-
facturer’s instructions with an input of 500 ng total RNA. 
To monitor the assay performance and to evaluate the inter-
assay BeadChip variability between the experiments, an 
inner-assay control consisting of 500 ng total RNA pooled 
from RNA isolated from several cultured breast cancer cell 
lines was used in each experiment [36].
Data analysis
Scanned data were uploaded into GenomeStudio software 
version 2011.1 via the WG-DASL gene expression module 
for further analysis. The average signal, detection P value, 
bead standard error and average beads were used to quantile 
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normalize the data in the statistical language R (www.r-proj 
ect.org) using the “Lumi” package [11].
To identify significantly differentially expressed genes, 
three steps were followed: sample exclusion criterion, 
Table 1  Clinical information
Samples 
Age at 
diagnosis 
(years) ER PR HER2/neu
Metastasis-
free period 
(months)
First metastasis 
site/s 
Subsequent 
metastasis site/s follow-up (months)
Discovery
1 41 0 0 0 9 brain 14
2 48 0 0 0 51 brain 55
3 62 0 0 0 7 brain 8
4 51 0 0 0 16
brain + lung + 
pleura 23
5 51 0 0 1 12 brain 18
6 53 0 0 0 16 brain + liver 18
7 41 0 0 0 25 brain + lung liver 54
8 49 0 0 0 37 brain + lung skin 39
13 52 0 0 1 12 bone + brain 13
9 38 0 0 0 23 skin + lung brain + bone 41
10 58 0 0 0 8 lung brain 20
11 58 0 0 0 30 liver brain 45
12 35 0 0 0 29 bone brain 63
14 45 0 0 0 4 skin 9
15 44 0 0 0 22 bone 35
16 35 0 0 0 7 liver + lung 18
17 40 0 0 0 33 bone + lung 65
18 66 0 0 0 5 pleura 12
19 57 0 0 0 14 bone + lung + pleura 22
20 45 0 0 1 17 liver + bone 29
21 70 0 0 0 17 liver + bone + lung 20
22 44 0 0 0 9 bone + lung 22
Validation
1 49 0 0 1 19 brain 19
2 39 0 0 0 51 brain 60
3 53 0 0 1 63 brain 69
4 56 0 0 0 6 brain 7
5 35 0 0 0 23 brain 118
6 39 0 0 0 59 brain 88
7 74 0 0 0 8 brain 14
8 29 0 0 0 116 brain 154
9 49 0 0 1 13 brain bone 50
10 38 0 0 0 12 brain lung + skin 16
11 53 0 0 1 35 brain other breast 169
12 59 0 0 1 19 brain lung + liver 52
13 47 0 0 1 16 brain + lung 18
14 69 0 0 1 14 skin 39
15 56 0 0 0 13 bone 28
16 57 0 0 0 61 bone + lung 61
17 69 0 0 1 7 liver 7
18 58 0 0 0 9 pleura 12
19 31 0 0 0 12 pleura liver + bone 12
20 36 0 0 0 159 lung kidney 241
Age at diagnosis in years; metastasis-free periods and follow-up in months. For ER, PR, HER2/neu status: 0 = negative, 1 = positive
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reliable probe selection and gene expression comparisons. 
Sample exclusion criterion and probe selection method were 
described previously [36]. For the gene expression compar-
ison, Biometric Research Branch ArrayTools (BRB-array 
tool (V4.3.1)) was used [51]. Within BRB, the 4150 most 
reliable probes for FF samples were exposed to the class 
comparison algorithm to identify differentially expressed 
genes with a maximum P value of 0.05 after 10,000 permu-
tations multiple correction to determine significance.
Pathway analysis
Pathway analysis was done by two different methods. Firstly, 
the differentially expressed genes (resulted from the gene 
expression comparisons of samples with brain metastasis 
compared to samples with metastasis to other organs) was 
submitted to Ingenuity Pathway Analysis (Ingenuity, Moun-
tain View, CA). Secondly, all reliably profiled genes were 
submitted to the Global Test [16] (version 4.4.0) to associ-
ate Biocarta pathways (www.bioc arta .com) to the groups 
of samples metastasizing to brain or to other organs. The R 
version 2.4.1 (www.r-proj ect.org) was used to run the Global 
Test package. A P value for a pathway was considered sig-
nificant when the univariate P value of the test as well as the 
P value calculated by 1000 re-samplings were both < 0.05. 
In addition, The lists of differentially expressed probes were 
uploaded into the function annotation tool DAVID version 
6.7 [9] to functionally annotate the differentially expressed 
genes. DAVID was used with the data basses and settings 
that are preselected by default. Statistical analyses and mul-
tiple testing correction procedures are those included in the 
DAVID analyses [21].
In vitro BBB model
Tissue culture procedures
Human umbilical vein endothelial cells (HUVECs, Sci-
enCell) were cultured in endothelial cell medium (ECM, 
ScienCell) supplemented with endothelial cells growth fac-
tors, 5% fetal bovine serum and Penicillin/Streptomycin. 
HUVECs were used between passage 2 and 5. Human astro-
cytes (ScienCell) were cultured in astrocytes medium (AM, 
ScienCell) supplemented with astrocyte growth factors, 2% 
fetal bovine serum and Penicillin/Streptomycin. Human 
astrocytes were used between passage 2 and 5. No further 
authentication was performed for this study for HUVECs 
and human astrocytes. Three breast cancer cell lines which 
had proven to be able to cross the BBB were used: MDA-
MB-231, MDA-MB-231-BM (a breast cancer cell line 
that metastasize specifically to brain) [3] and SUM159PT 
[45]. The characterization of the breast cancer cell lines are 
summarized (Supplementary Table 1). The tumor cell lines 
and normal fibroblasts (isolated from non-cancerous tissue) 
were previously characterized [19, 46], and were cultured in 
RPMI medium supplemented with l-glutamine, 10% fetal 
bovine serum and Penicillin/Streptomycin. T cells were 
isolated, activated and transduced as described previously 
[24, 55]. Two types of T cells were used: T cells that were 
transduced with an empty vector, referred to as “T cells”, 
and T cells that were transduced with a T cell receptor spe-
cific for MAGE-C2/HLA-A2 vector, referred to as “antigen-
specific T cells”. The later T cells allowed studies into the 
role of antigen-specific activation of T cells, to which end 
SUM159PT cells were used as these cells express the cog-
nate antigen (MAGE-C2/HLA-A2). Both types of T cells 
were cultured in RPMI media, supplemented with 10% fetal 
bovine serum and IL-2 (360 IU/mL, Chiron, Amsterdam, 
The Netherlands), and Penicillin/Streptomycin. The T cell 
transduction process, validation of TCR expression by flow 
cytometry and particular culture conditions by allogeneic 
feeder cells are described in [24, 55].
Construction of the in vitro BBB assays
To develop a BBB model, HUVECs were co-cultured with 
human astrocytes on opposite sides of a transwell insert 
[13]. Twenty-four-wells transwell polycarbonate inserts (sur-
face area 0.33 cm2, pore size 3 µm, Becton Drive, Franklin 
Lakes, NJ, USA) were coated with 2% gelatin (Sigma) for 
45 min. The transwell inserts were placed upside-down and 
~ 100,000 human astrocytes/inserts were seeded at the bot-
tom side of the inserts. The cells were allowed to adhere 
for 3 h at 37 °C in a 5%  CO2 incubator and were fed every 
15–30 min. After 3 h, inserts were flipped and placed in 
24-well plates. 1 mL of astrocyte media was added to the 
lower chamber and astrocytes were allowed to grow for 
1 day. Fifty-thousand endothelial cells were plated on the 
upper chamber of the inserts and the cultures were placed in 
the incubator for 3 days. The permeability of the BBB model 
was verified by adding trypan blue dye to the upper cham-
ber and incubating the model for 30 min at 37 °C. Medium 
from the lower chamber was collected and absorbance was 
measured at 595 nm. The permeability of the BBB model 
by trypan blue was included in duplicate in each experiment.
In vitro BBB‑T cell response functional studies
To investigate the influence of T lymphocytes on the abil-
ity of tumor cells to cross the BBB, MDA-MB-231, MDA-
MB-231-BM and SUM159PT breast cancer cells were 
co-cultured with T cells (no specific binding occurred 
between T cells and breast cancer cells). In addition, 
SUM159PT breast cancer cells were co-cultured with 
antigen-specific T cells (specific binding occurred between 
T cells and breast cancer cells). The optimal ratio of tumor 
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cells and T cells was achieved following a titration to reach 
the best balance between cell killing and migration. The 
co-culture ratio of breast cancer cells over T cells was 
3:1. After co-culturing for 3 days, T cells were removed 
by three washes using PBS. The breast cancer cells were 
harvested and labelled with 5 µM CFMDA cell tracker 
green (Invitrogen) for 45 min in serum-free medium. The 
breast cancer cells were collected and re-suspended in 
RPMI medium supplemented with l-glutamine, 10% fetal 
bovine serum and Penicillin/Streptomycin. Ten thousand 
cells were seeded in the upper chamber of the BBB model 
and incubated overnight at 37 °C. The cells which had 
passed through were recorded by confocal microscopy of 
the lower chamber after removing the transwell inserts.
To investigate whether the cytokines secreted by T 
cells are responsible for the changes of breast cancer cells, 
cells of the three breast cancer cell lines were incubated 
with 5 ml conditioned media collected from T cells for 
3 days. Then breast cancer cells were washed, harvested 
and labelled using the same method as described above. 
Ten-thousand cells were seeded on the upper chamber of 
the insert and incubated overnight at 37 °C. As a control, 
ten-thousand breast cancer cells of the three breast cancer 
cell lines, without exposure to either T cells or to condi-
tioned media from T cells, were used. These experiments 
were repeated 10 times. As a negative control, fibroblasts 
isolated from non-cancerous tissue were used.
To study the effect of IL-2 (which is essential in cultur-
ing T cells) and IFN-γ (a cytokine produced by T cells) 
the three types of breast cancer cell lines were incubated 
with IL-2 (360  IU/ml) and with IFN-γ (10 and 20 µg, 
Bio-Connect, Huissen, The Netherlands) separately for 
3 days. Subsequently, breast cancer cells were washed, 
labelled with cell tracker green and seeded in the upper 
chamber of the BBB model. These experiments were 
repeated three times. Moreover, to study the effects of T 
cells, conditioned media of T cells, IL-2 and IFN-γ, on 
the permeability of the BBB model, they were added to 
the upper chamber of the BBB model and incubated over-
night. Subsequently, the permeability of the BBB model 
was investigated by adding trypan-blue dye (20% in RPMI 
media) to the upper chamber and incubated for 30 min 
at 37 °C. Medium from the lower chamber was collected 
and absorbance was measured at 595 nm. In addition, the 
effect of the mentioned factors on the permeability of the 
BBB model was checked by seeding breast cancer cells 
in the upper chamber of the BBB model overnight. These 
experiments were repeated three times.
Confocal laser‑scanning microscopy and Quantification 
of the migrated cells
Confocal images were obtained using a Zeiss LSM510 con-
focal laser-scanning microscope equipped with a 488 nm 
Argon-laser and a Plan-Neofluar 20× objective with NA 0.5 
(Zeiss, Oberkochen, Germany). Images were made with a 
pixelsize of 0.9 µm. Pictures were submitted to ImageJ soft-
ware version 1.49S (http ://www.fiji .sc) and used to calculate 
the number of cells per  mm2.
Proteomics measurements
MDA-MB-231 and MDA-MB-231-BM breast cancer cells 
were co-cultured with T cells in 3: 1 ratio, and SUM159PT 
was co-cultured with antigen-specific T cells for 3 days 
(following the same method described earlier). As controls, 
MDA-MB-231, MDA-MB-231-BM and SUM159PT cells 
were cultured without T cells for 3 days. All cell cultures 
were washed three times with PBS to remove T cells before 
they were scraped and collected in 1.5 mL Eppendorf tubes. 
Three additional washing steps with PBS were applied. After 
removing the supernatant, the cell pellets were immediately 
snap-frozen on dry-ice and stored in − 80 °C until the time 
of preparation. After thawing the samples, they were pre-
pared and measured on nano LC as described previously 
[35].
Proteomics data analysis
From the raw data files of the Orbitrap Fusion mass spec-
trometer, MS/MS spectra were extracted and converted 
into mgf files using MSConvert of ProteoWizard1 (version 
3.0.06245). All mgf files were analyzed using Mascot (ver-
sion 2.3.02; the Matrix Science, London, UK), which was 
used to perform searches against the Uniprot_sprot_2014_09 
database; Homo sapiens species restriction; 66,244 
sequences. For the database search the following settings 
were used: a maximum of two miss cleavages, oxidation as 
a variable modification of methionine, carbamidomethyla-
tion as a fixed modification of cysteine and trypsin was set as 
enzyme. A peptide mass tolerance of 10 ppm and a fragment 
mass tolerance of 0.5 Da were allowed. An ion score of 40 
was used as cut-off value.
Scaffold software (version 4.4.3, Portland, OR) was used 
to summarize and filter MS/MS based peptides and pro-
tein identifications. Protein identifications were accepted if 
they could be established at greater than 99.0% probability 
and contained at least two identified peptides. Proteins that 
contained similar peptides and could not be differentiated 
based on MS/MS analysis alone were grouped. Using these 
criteria, Scaffold generated a list of identified proteins (Mini-
mum: 6% coverage and 2 peptides), including the number of 
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sequenced peptides that corresponded to these proteins. The 
identified proteins of breast cancer cells (of the three cell 
lines) that were co-cultured with T cells were compared to 
those of the breast cancer cells cultured without the T cells. 
The comparison was done based on 2 sample t test, and the 
P values of all proteins were calculated and corrected for 
multiple variants using Benjamini–Hochberg. A protein was 
considered as a differentially expressed protein if P < 0.05, 
and all three breast cancer cell lines in one group showed the 
same direction of expression.
The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the 
PRIDE [60] partner repository with the dataset identifier 
PXD006750.
GBP1 silencing
To study the role of GBP1 in crossing the BBB by the tumor 
cells, silencing transfection experiments were performed. A 
mix of four siRNA sequences that target GBP1 mRNA and 
another mix of non-targeting siRNA (referred to as siSham) 
were obtained from Dharmacon (GE health care, The Neth-
erlands). Silencing experiments were performed using trans-
fection buffer 1, following the manufacturer’s instructions 
(Dharmacon, GE health care, The Netherlands). MDA-
MB-231 and MDA-MB-231-BM breast cancer cell lines 
were transfected for 24 h. RNA was isolated using RNeasy 
Micro Kit (Qiagen), and the silencing efficiency was evalu-
ated by reverse transcriptase quantitative PCR (RT-qPCR) 
using TaqMan gene expression assay (Applied Biosystems).
When siGBP1 proved to be efficient, the transfection 
experiments were performed for 24 h, then breast cancer 
cells were co-cultured with T cells (3:1 ratio) for an addi-
tional 24 h. The co-culturing time was reduced to 24 h, 
well within the effective period of siGBP1. Afterward, T 
cells were washed away with PBS, and breast cancer cells 
were harvested and labelled with green tracker as described 
above. Ten-thousand cells were seeded on the upper cham-
ber of the BBB model as described above.
Immunohistochemistry Formalin fixed, paraffin embed-
ded (FFPE) tissue samples that morphologically matched 
the primary FF tissues were used to perform immunohis-
tochemistry. We retrieved 11 FFPE samples of the 22 FF 
samples that were used for discovery. The T cell markers 
were stained with an automated IHC staining system (Ven-
tana BenchMark ULTRA; Ventana Medical System Inc. 
Tucson, AZ). CD3 (0.4 µg/mL, clone 2GV6, Ventana, Tus-
can, AZ) antibody was used as general marker for T cells; 
CD4 (2.5  µg/mL, clone PS35, Ventana, Tuscan, AZ) and 
CD8 (1:100 dilution, clone C8/144B, Dako, Heverlee, Bel-
gium) were used as markers for T helpers and T cytotoxic 
subsets, respectively. The staining was performed according 
to the manufacture instructions. In addition, GBP1 (1:250 
dilution, Santa Cruz Biotechnology, Heidelberg Germany) 
was used according to the manufacture instructions. In addi-
tion to the 11 FFPE samples of the discovery set, we used 20 
independent samples for extra validation. The clinical infor-
mation of the samples is summarized in Table 1.
In vivo mouse model
T cell isolation and tissue culture
T cells were obtained from the spleen of 4–6-week-old FVB 
mice weeks. Splenocytes were sorted using anti-mouse 
CD4-Pe (BD Pharmigen catalog. 553048) and activated with 
anti-mouse CD3e clone 145-2C11 (BD Pharmigen catalog. 
553066) coated plates, soluble anti-mouse CD28 (37.51) 
(Tonbo Biosciences catalog. 70-0281-U500), and mouse 
IL-2 (Miltenyi Biotec catalog. 130-094-054). The ErbB2-
P cell line was established from MMTV driven-NeuNT 
transgenic mammary tumors in mice [34]. They express 
Luciferase and gfp. ErbB2-P are cultured in vitro in DME 
media supplemented with 10% fetal bovine serum (FBS), 
2 mM l-Glutamine, 100 IU/ml penicillin/streptomycin, and 
1 mg/ml amphotericin B. The ErbB2-P was co-cultured with 
T cells in RPMI medium supplemented with 10% FBS and 
Penicillin–Streptomycin for 3 days and then sorted out and 
injected in syngeneic animals into the heart. 3 weeks later, 
metastasis burden was analyzed by bioluminescence imag-
ing (BLI).
qRT‑PCR
RNA (QIAGEN) from sorted gfp + ErbB2-P cancer cells 
was used to generate cDNA (iScript cDNA Synthesis Kit 
Bio-Rad catalog. 1708890). Gene expression was analyzed 
using SYBR green gene expression assays  (GoTaq® qPCR 
Master Mix Promega catalog. A6002). Primers: Gbp1 
(Sequence of the primer 5–3): 5′-3′GGG CAG CTG TCT 
TTG GGT AGAC, 3′-5′AGC ATG AGG CCC TAG GAG CTGT. 
Quantitative PCR reaction was performed on QuantStudio 6 
Flex Real-Time PCR System (Applied Biosystems) and ana-
lyzed using the software QuantStudio 6 and 7 Flex Software.
Flow cytometry
ErbB2-P and T cells were isolated from the co-culture based 
on gfp expression using FACS ARIA Ilu sorter.
Animal experiments
All animal experiments were done in accordance with a 
protocol approved by the CNIO, Instituto de Salud Carlos 
III and Comunidad de Madrid Institutional Animal Care 
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and Use Committee. ErbB2-P cells were injected intracar-
diacally. Briefly, a cell suspension containing  105 ErbB2-P 
cells in a volume of 100 μl was injected in the left cardiac 
ventricle of anesthetized 4–6-week-old FVB mice. Tumor 
burden was evaluated by bioluminescence imaging using 
the IVIS-200 imaging system from Xenogen as previously 
described. Metastases were defined with BLI as those with 
signal equal or above  2x103 photon flux.
Statistics
P value is calculated using two-tailed t test.
Free‑floating immunofluorescence
Tissue for immunofluorescence was obtained after overnight 
fixation with PFA 4% at 4 °C. Slicing of the brain was done 
using a sliding microtome (Fisher). Brain slices (80 μm) 
were blocked in NGS 10%, BSA 2%, Triton 0.25% in PBS 
for 2 h at room temperature (RT). Primary antibodies were 
incubated overnight at 4C in the blocking solution and the 
following day for 30 min at RT. After extensive washing 
in PBS-Triton 0.25%, the secondary antibody was added in 
the blocking solution and incubated for 2 h. After extensive 
washing in PBS-Triton 0.25%, nuclei were stained with Bis-
Benzamide for 7 min at RT. Primary antibody GFP (Aves 
Labs, ref. GFP-1020, 1:1000). Secondary antibody is Alexa-
Fluor anti-chicken 488 (Invitrogen).
Quantification of brain metastases histology
80 um sections were obtained from each brain generating 10 
series. One series containing 10–12 slices representative of 
the whole organ was used for immunofluorescence analysis. 
The staining of gbp1 was performed and positive lesions 
were quantified under a fluorescence microscope. Total num-
ber of metastases per series was obtained and plotted.
Results
Breast cancers associated with brain metastasis 
express genes involved in the T lymphocyte 
response
Comparing the gene expression profiles of primary breast 
cancer samples that developed brain metastasis with those 
that developed metastasis to other organs resulted in 298 
differentially regulated genes at P < 0.05 (Fig. 1a). Among 
the significant genes, 176 were up-regulated in the group of 
tumors associated with brain metastasis, while 122 genes 
were up-regulated in the group associated with metastasis 
to other organs. To prioritize these genes, we ran functional 
and pathways analyses. The function annotation tool DAVID 
revealed that “regulation of T cell activation” was most 
prominent among the samples associated with brain metas-
tasis (P value < 0.00002; enrichment score of 6.02). Path-
way analysis pointed to a prominent involvement of the “T 
lymphocyte response” based on both methods (Ingenuity and 
Global testing) (Tables 2, 3). Moreover, all involved genes in 
the pathway were up-regulated in the group associated with 
the brain metastases (Fig. 1b, Table 2).  
We screened 11 tumors for the presence of tumor infil-
trating lymphocytes (TILs) according to the criteria of the 
TILs working group 2014 [48], and found that TILs were 
confined to the stroma surrounding tumor islands in the pri-
mary breast cancer samples of patients who had developed 
metastasis to other organs (Fig. 1c, d). In contrast, TILs had 
invaded the tumor island in patients who had developed cer-
ebral metastases. This observation suggested that T cells 
may play a role in increasing the ability of breast cancer 
patients to develop brain metastasis.
T lymphocytes increase the ability of breast cancer 
cells to cross an in vitro BBB model
To functionally validate the importance of T cells to stimu-
late brain metastasis, we developed an in vitro BBB model 
and used three breast cancer cell lines (MDA-MB-231, 
MDA-MB-231-BM, and SUM159PT). These cell lines 
are known for their ability to cross the BBB [3, 45], and 
they all were able to cross the BBB of our in vitro model. 
However, the number of cells that crossed the artificial 
BBB overnight was very limited (< 10 cells). We co-cul-
tured breast cancer cells with T cells that were isolated 
from normal donors for 3 days, removed the T cells and 
added the breast cancer cells to the BBB model (Fig. 2a). 
The number of breast cancer cells that crossed the BBB 
increased significantly (> 300–650 cells) (Fig. 2b, c). 
To investigate if the interaction between breast cancer 
cells and T cells was necessary for the dramatic effect 
that we observed, we run two experiments. First, we incu-
bated breast cancer cells with conditioned media from 
T lymphocytes (without including T cells) and found an 
increased ability of breast cancer cells to cross the BBB 
albeit less significantly (> 80–250 cells) (Fig. 2b, c). Sec-
ond, we co-cultured SUM159PT breast cancer cells (that 
express the cognate antigen MAGE-C2/HLA-A2) with 
antigen-specific T cells  (CD3+ T lymphocytes transfected 
with MAGE-C2/HLA-A2 vector). The specific interaction 
between the breast cancer cells and the T lymphocytes 
increased the ability of the breast cancer cells to cross 
the BBB significantly (> 400 cells) (Supp. Figure 1). To 
investigate if T cells have the same effect on normal cell, 
we replaced the tumor cells for normal fibroblasts. Co-cul-
turing fibroblasts with T lymphocytes, or with conditioned 
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media from T lymphocytes, did not change their ability to 
cross the BBB (Fig. 2b, c). To investigate if T lymphocytes 
have a direct influence on the permeability of the BBB 
in the model, we added T cells, antigen-specific T cells, 
and their conditioned media to the upper chamber of the 
model. T lymphocytes were able to cross the BBB, but 
neither the T cells, nor their conditioned media, changed 
the permeability of the BBB (data not shown). We also 
tested a possible direct effect of interferon gamma (IFNγ) 
secreted by the T cells, on the tumor cells, by incubat-
ing the breast cancer cells with several concentrations of 
IFNγ, but no effect on the ability to cross the BBB model 
Fig. 1  Breast cancer samples associated with brain metastasis express 
genes involved in the T lymphocyte response. a Heat map of the 298 
differentially expressed probes between the primary breast cancer 
samples that developed metastases, with or without brain metastasis. 
b Pathway analysis revealed the involvement of the T cells response 
in the formation of brain metastasis. In this “Antigen Presenting Path-
way”, the up-regulated genes in the samples that developed brain 
metastasis are shown in purple. c (1) In the primary breast cancer 
samples associated with brain metastasis, T cells invade the tumor tis-
sue. (2) In the samples associated with metastasis to other sites, the 
T cells remain in the tumor stroma. (CD3, 100×). d Percentages of 
TILs in the primary breast cancer samples of patients who developed 
metastasis to brain or to other organs
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was noticeable. In addition, we tested the effect of IL-2 (a 
required growth factor for culturing T lymphocytes) on 
tumor cells, but no facilitating effect was observed either 
(Fig. 2d). Both IFNγ and IL-2 did not change the perme-
ability of the BBB (data not shown). These experiments 
confirmed that T lymphocytes and their secreted factors 
increase the ability of breast cancer cells to cross the 
in vitro BBB model, and also proved that antigen-specific 
interaction between breast cancer cells and T lymphocytes 
is not necessary to promote the discovered facilitating 
effect.
GBP1 protein is involved in changing the ability 
of breast cancer cells in crossing the BBB
Next, we aimed to identify the changes that occur in breast 
cancer cells after co-culturing with T lymphocytes respon-
sible for their increased capacity to pass through the BBB. 
Therefore, we measured the proteome of breast cancer cells 
before and after co-culturing with T cells by mass spec-
trometry. The proteomics comparisons lead to the identi-
fication of 21 differentially regulated proteins between the 
two groups (out of over 2500) at P < 0.05, 12 of which were 
Table 2  Top ten canonical pathways (ingenuity)
Ingenuity Canonical 
Pathways log(p-value) Ratio * Genes 
Communication between 
Innate and Adaptive 
Immune Cells 1.65E-08 9.82E-02 
CXCL10, IFNG, HLA-C, HLA-DRB3, TLR8, 
CCL3L1/CCL3L3, CD83, CD8A, TLR9, HLA-DRB5, 
TNFSF13B
Antigen Presentation 
Pathway 1.44E-06 1.67E-01 
IFNG, HLA-DOA, HLA-DQB2, HLA-C, HLA-DRB3, 
TAP1, HLA-DRB5
Allograft Rejection 
20-E22.760-E77.1gnilangiS
IFNG, PRF1, HLA-DOA, HLA-DQB2, HLA-C, HLA-
DRB3, HLA-DRB5
Type I Diabetes Mellitus 
Signaling 4.71E-06 8.26E-02 
CD247, IFNG, PRF1, HLA-DOA, HLA-C, IFNGR2, 
STAT1, CASP8, CD3D, HLA-DRB5
Pathogenesis of Multiple 
10-E00.460-E29.4sisorelcS CXCL10, CXCL11, CXCL9, CXCR3
T Helper Cell 
Differentiation 7.10E-06 1.11E-01 
IFNG, HLA-DOA, IL12RB1, ICOS, IL10RA, IFNGR2, 
STAT1, HLA-DRB5
OX40 Signaling Pathway 9.83E-06 7.22E-02 
CD247, HLA-DOA, HLA-DQB2, HLA-C, HLA-DRB3, 
CD3D, HLA-DRB5
Cytotoxic T Lymphocyte-
mediated Apoptosis of 
Target Cells 4.90E-05 1.28E-01 CD247, PRF1, HLA-C, CASP8, CDd3D
Crosstalk between Dendritic 
Cells and Natural Killer 
20-E55.750-E59.8slleC
IFNG, PRF1, HLA-C, HLA-DRB3, CD83, TLR9, ITGAL, 
HLA-DRB5
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 2.42E-04 7.00E-02 
IFNG, HLA-DOA, CXCL13, TLR8, TLR9, HLA-DRB5, 
TNFSF13B
Red: up-regulated, and green: down-regulated, in primary breast cancers samples associated with metastasis to brain
*Ratio of genes found over their total number in a particular pathway
Table 3  Top ten canonical 
pathways resulted from global 
testing
*P value calculated by 1000 re-samplings
Global test canonical pathways Comparative P 
 value*
P value
The 41BB-dependent immune response 0.004 0.0016
Chaperones modulate interferon signaling pathway 0.004 0.0043
Th1–Th2 differentiation 0.008 0.0045
Roles of arrest independent recruitment of Src Kinases in GPCR signaling 0.012 0.0055
X arrest ins in GPCR desensitization 0.012 0.0101
B lymphocyte cell surface molecules 0.011 0.0117
Role of Tob in T cell activation 0.006 0.0118
Dendritic cells in regulating TH1 and TH2 development 0.009 0.0144
Activation of Csk by cAMP dependent protein kinase inhibits signaling 
through the T cell receptor
0.012 0.0180
NO2-dependent IL-12 pathway in NK cells 0.015 0.0187
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up-regulated in the cells exposed to the T cells (Tables 4, 
5). The 21 differentially regulated proteins were compared 
to the 298 differentially expressed genes identified in the 
mRNA gene expression arrays (Fig. 3a) and GBP1 was the 
only protein that matched at the mRNA level. GBP1 protein 
was exclusively measured and identified in all three breast 
cancer cell lines that were co-cultured with T lymphocytes 
(P < 0.001), and the GBP1 gene was up-regulated in the pri-
mary breast cancer samples that developed brain metastasis 
(P < 0.05 and 1.5 fold change). Furthermore, staining for 
GBP1 was positive only in the samples of the primary breast 
cancers of the patients who developed brain metastases, 
while not in the samples of patients who developed metasta-
sis to other organs (Fig. 3b, c). Furthermore, the tumor areas 
with and without the expression of GBP1 were morphologi-
cally indistinguishable, except for the presence of TILs in 
the former. To further confirm our findings, we validated 
the upregulation of GBP1 after co-culturing breast cancer 
Fig. 2  T lymphocytes increase the ability of breast cancer cells to 
cross the BBB in the in  vitro model. a Schema of experimental 
design. b Three breast cancer cell lines (MDA-MB-231, MDA-MB-
231-BM, and SUM159PT) showed a limited ability to cross the 
in  vitro BBB (left column, lower three fields). Following co-cul-
ture with T cells, the ability of breast cancer cells to cross the BBB 
increased significantly (middle column, lower three fields). Con-
ditioned media of T cells also increased the ability of breast cancer 
cells to cross the BBB, but to a lesser extent (right column, lower 
three fields). Neither T cells, nor their media, facilitated fibroblasts to 
cross the BBB (upper row). All experiments were repeated ten times. 
c Quantitative representation of B (error bars indicate standard devia-
tion) (Br. Ca. = breast cancer). d IFNγ and IL-2 did not change the 
ability of breast cancer cells to cross the BBB. These experiments 
were repeated three times
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cells with T lymphocytes by RT-PCR (Fig. 3d). In addition, 
immunohistochemical staining for GBP1 of 20 independ-
ent samples of which 13 developed brain metastasis showed 
positivity only in the ER- breast cancer samples of patients 
who developed brain metastasis (Fig. 3e).
The prominent effect of GBP1 on the capacity of tumor 
cells to cross the modelled BBB was examined by silenc-
ing experiments. GBP1 was silenced in MDA-MB-231 and 
in MDA-MB-231-BM breast cancer cell lines using pooled 
probes against GBP1. However, the expression of GBP1 was 
not affected when using siSham (negative control) (Fig. 4a). 
Subsequently, the cancer cells were co-cultured with T cells. 
The silenced GBP1 breast cancer cells showed a significant 
decrease in the ability to cross the BBB following co-cul-
tured with T cells as compared to siSham cells, or to breast 
cancer cells that were not affected by silencing. A 30–70 
fold decline in crossing of the BBB was reached following 
silencing of GBP1 (Fig. 4b, c).
T lymphocytes increase the ability of breast cancer 
cells to induce brain metastases in a mouse model
To functionally test the ability of T cells to promote brain 
metastasis, we used a cancer cell line (ErbB2-P) estab-
lished from a spontaneous ErbB2 + mammary tumor 
derived from MMTV driven-NeuNT transgenic mice 
[34]. This cell line does not have the ability to target 
the brain when injected in the systemic circulation [58]. 
The ErbB2-P cells were co-cultured with T cells, which 
were previously activated in vitro (Fig. 5a). Sorted cancer 
cells were initially interrogated by qRT-PCR to analyze 
Gbp1 levels. Analysis of three independent experiments 
showed that co-culture of ErbB2-P with activated T cells 
induces a significant increase in Gbp1 expression levels 
in the cancer cells (Fig. 5b). To interrogate the influ-
ence of T cells on metastasis, ErbB2-P cells were intra-
cardially inoculated in immunocompetent syngeneic mice 
(Fig. 5a). 21 days after inoculation, most of the clones 
of the ErbB2-P cell line were not able to generate brain 
metastasis with only one animal out of 12 (8.3%) show-
ing bioluminescence in the brain (Fig. 5c, d, f, h). This 
limited potential to grow in the brain of the parental cell 
line dramatically increased when cancer cells inoculated 
had been previously in contact with T cells. Seven out 
of thirteen (53.8%) animals inoculated with ErbB2-P co-
cultured with T cells developed brain metastasis (Fig. 5c, 
d, f, h). This sixfold increase in the ability to generate 
secondary tumors in the brain was not mimicked in other 
organs since ex vivo analysis of lungs, liver, kidneys, 
adrenal glands, and bones (data not shown) did not show 
any difference nor in the percentage of animals affected 
(ErbB2-P: 25% mice with extra-cranial disease; ErbB2-
P + T cells: 33.3%) neither in the bioluminescence signal Ta
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from ex vivo analysis (Fig. 5e, g, i). We conclude that 
activated T cells are sufficient to increase the ability of 
breast cancer cells to develop brain metastasis. To investi-
gate the brain metastatic phenotype in more detail, in par-
ticular if there was increased access of cancer cell clones 
in the brain parenchyma, or if there is also an increased 
ability to colonize the brain, we microscopically exam-
ined the brains. Most brains inoculated with ErbB2-P 
cells did not show any cancer cell, even at the single cell 
level with the exception of the BLI + one (Fig. 5j, k). 
The ErbB2-P cells that were co-cultured with T cells 
consistently showed multiple cancer cell clones within 
the perivascular spaces (indicative of the ability to get 
access to the brain parenchyma; Fig. 5j, k), suggesting an 
increased ability to cross the BBB. In addition, increased 
size and invasive fronts at the metastatic deposits was 
observed, indicative of increased capability of paren-
chyma invasion (Fig. 5l, m, in comparison with Fig. 5n, 
o). This observation suggests an additional influence of 
T cells providing cancer cells with further capabilities to 
Fig. 3  Immunohistochemistry for GBP1 in primary breast cancer 
samples. a Venn diagram illustrating the overlap of differentially 
regulated genes and proteins. b (I) Expression of GBP1 protein in 
primary breast cancers with brain metastasis. (II) GBP1 protein in 
primary breast cancers with metastases to organs other than brain. c 
Semi-quantitative results of immunohistochemistry for GBP1 using 
the discovery sample set. The color scale represents the scores of the 
immunohistochemical staining, ranging from 0  =  no expression to 
3 = highest expression. d RT-PCR results of the GBP1 expression in 
MDA-MB-231 and MDA-MB-231-BM before and after co-culturing 
with T lymphocytes. For both cell lines, the GBP1 expression before 
and after co-culturing with T cells differ significantly. Bars indicate 
mean values  ±  SEM, from three independent experiments. e Semi-
quantitative results of immunohistochemistry for GBP1 using 20 
independent primary breast cancer samples. The color scale repre-
sents the scores of the immunohistochemical staining, ranging from 
0 = no expression to 3 = highest expression
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advance from the first extravasation compartment. We 
conclude that the influence of the T cells extends beyond 
making the breast cancer cells pass the BBB, but also 
makes them invade the brain tissue.
Discussion
The identification of the mechanisms and underlying 
molecular pathways that cancer cells use to cross the 
BBB is important for the development of strategies to 
Fig. 4  GBP1 affects crossing of breast cancer cells through the BBB. 
a RT-PCR results of GBP1 expression showing successful silencing. 
The expression of GBP1 in breast cancer cells was compared to that 
of the non-targeting siRNA (siSham) (n = 3; bars indicate standard 
deviation). These experiments were repeated twice, and the results 
were reproducible. b Breast cancer cells silenced for GBP1 and co-
cultured with T cells show a reduction in their ability to pass the 
BBB (right column) as compared to the breast cancer cells that were 
silenced for siSham (middle column). As a control, breast cancer 
cells not silenced for GBP1, were co-cultured with T cells, showed 
their ability to cross the BBB (left column). These experiments were 
repeated twice, and the results were reproducible. c Quantitative 
results of B; error bars indicate standard deviation). The number of 
breast cancer cells that were able to cross the BBB had decreased sig-
nificantly after silencing GBP1. d Cartoon illustrating the function of 
GBP1
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prevent cerebral dissemination. In this study, we found 
the T lymphocyte response most prominently involved in 
the formation of cerebral metastases of ER- breast cancer 
patients. The involvement of T lymphocytes in the meta-
static potential of breast cancer has been noticed previ-
ously, particularly implicating induction of immune tol-
erance by regulatory T lymphocytes [2, 5, 33, 39]. The 
present results, however, reveal an entirely different effect 
of T cells, namely, that T lymphocytes and their secreted 
factors change the expressional profiles of tumor cells, 
thereby increasing their ability to cross the BBB. It is 
known that the immune system mediates primary tumors 
in their proliferation and invasion by secretion of inflam-
matory cytokines, chemokines, autoantibodies, proteases, 
and more. The role of the immune system in the formation 
of metastases is complex and far from understood [1, 8, 28, 
31]. To some extent, the present findings are reminiscent 
of the T cell involvement inducing receptor activator of 
nuclear factor-κB (RANK) signaling causing pulmonary 
metastases in a mouse breast cancer model [56]. However, 
the results obtained using human breast cancer samples 
show that the presence of T cells correlates with the for-
mation of cerebral metastasis. This finding has not been 
reported previously.
The discovery of T cell involvement in the formation 
of cerebral metastasis was based on a relatively small 
series of samples of breast cancer patients. Therefore, 
we confirmed our findings at the functional level using 
in vivo and in vitro models. Injecting mice with breast 
cancer cells that were co-cultured with T cells proved that 
T cells play an important role in increasing the ability 
of breast cancer cells to cross the BBB and to develop 
brain metastasis. Interestingly, co-culturing breast cancer 
and T cells did not increase the tendency to metastasis to 
organs other than brain. The in vitro BBB model we used 
is composed of human endothelial cells and astrocytes, 
closely reflecting the normal barrier function of human 
BBB. The ability of breast cancer cells to cross the BBB 
improved significantly when the tumor cells were co-cul-
tured with T cells. The facilitating effect was observed 
after co-culturing with T cells isolated from normal donors 
as well as with antigen-specific T cells, indicative of anti-
gen independency. Incubation of the breast cancer cells 
with the conditioned media of the T cells showed similar 
results, pointing to the importance of particular factors 
secreted by T lymphocytes. In an effort to identify the fac-
tors that caused the facilitating effect, we incubated breast 
cancer cell with IFNγ that is secreted almost exclusively 
by T cells. Interestingly, IFNγ did not change the ability 
of breast cancer cells to cross the BBB, nor did it change 
the permeability of the BBB itself. Similar results were 
obtained when incubating breast cancer cells with IL-2. 
It could be argued that instead of single proteins, several 
secreted proteins and cytokines are necessary to induce 
the facilitating effect. The complex interplay between T 
cells and the humoral immune system was demonstrated 
in the MMTV-PyMT mouse model, where IL-4-expressing 
CD4 + T lymphocytes indirectly promote invasion and 
subsequent metastasis of mammary adenocarcinomas [8]. 
In another mouse breast cancer model, the effects of inter-
leukin (IL)-1β on the IL-17 expression of gamma delta 
(γδ) T cells were shown, affecting neutrophils and sup-
pression of CD8 + T cells, also leading to the formation 
of metastases [7].
Among the 21 differentially expressed proteins in the 
three breast cancer cell lines following co-culturing with T 
cells, only the GBP1 gene was found to be overexpressed 
in the set of primary breast cancer samples that developed 
brain metastasis. RT-PCR results confirmed that GBP1 
expression is significantly upregulated in breast cancer 
cells after co-culturing with T lymphocytes. Further con-
firmation of the expression of GBP1 was confirmed by 
immunohistochemistry in the discovery sample set and 
in an additional 20 independent samples. GBP1 positive 
cells were detected in tumor areas, where T lymphocytes 
invaded from the stroma in between the tumor cells. 
Human GBP1 is a secreted GTPase that is induced by 
IFNγ and mediate the antibacterial and antiviral activities 
of IFNγ [41]. The GBP1 protein binds to actin and plays a 
role in the remodeling of the fibrous actin structure thereby 
influencing cellular motility [14, 23, 41]. The regulation 
of the cytoskeleton and the remodeling of actin by GBP1 
is of a great relevance in process like migration, invasion, 
proliferation and defense against barrier function, a pos-
sible link with the increased passage through the BBB 
[22, 41, 46]. However, the relation with brain invasion 
seems more complex since GBP1-mediated actin remod-
eling also contributes to the regulation of the innate and 
adaptive immune defense [41]. Moreover, mutations in the 
GBP1 gene are among those related to the tumorigenesis 
of breast cancer [20] and the aggressive hormone-negative 
inflammatory subtype in particular [25]. In vitro studies 
revealed a role of GBP1 in tamoxifen resistance [12]. The 
GBP1 protein is also involved in resistance to docetaxelis 
of prostate cancer [10], and in a recent study, it was shown 
that it is one of the key molecules contributing to cancer 
radioresistance [15]. With respect to tumors other than 
breast cancer, GBP1 is considered to act as tumor sup-
pressor gene in colorectal cancer [4], and as an effector of 
EGFR-driven tumor cell invasion in glioblastomas [27]. In 
addition, GBP1 was found to promote lymph node metas-
tasis in esophageal squamosal cell carcinoma [26]. So far, 
GBP1 was not associated with brain metastasis of breast 
cancer. However, a recent study showed that the over-
expression of GBP1 protein among others was associated 
with metastasis in TNBC [42]. Obviously, its expression 
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sites, specific action, and possible partners involved in 
brain metastasis need further exploration. Most impor-
tantly, investigations in the effects of blocking its expres-
sion in vivo are needed to develop therapeutic strategies 
in preventing metastases to brain.
Our results highlight the importance of T lymphocytes 
and their secreted cytokines for the formation of brain 
metastasis originating from ER- breast cancers. This 
is new to current knowledge of the complex interplay 
between T lymphocytes and cancer cells. T lymphocytes 
change the expressional repertoire of breast cancer cells 
that promotes their ability to cross the BBB. At this point, 
subsequent studies are necessary to detail the role of any 
specific T cell subset in facilitating the breast cancers to 
cross the BBB. The up-regulation of the GBP1 gene and 
the over-expression of GBP1 protein seem to be crucial to 
this effect. The predictive value of this protein of the rise 
of cerebral metastases should be evaluated in prospective 
settings.
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